Back |
home / stock / pbyi / pbyi message board
Subject | By | Source | When |
---|---|---|---|
PBYi SOLID TUMORS APROVAL for FDA clay | CHARLIE125 | investorshub | 09/06/2019 1:49:43 PM |
$PBYI next aproval FDA for solid tumors | CHARLIE125 | investorshub | 09/06/2019 1:48:51 PM |
$PBYI | CHARLIE125 | investorshub | 08/22/2019 12:19:58 PM |
$PBYI i can say you pete that this $PBYI | CHARLIE125 | investorshub | 08/21/2019 1:28:41 PM |
$PBYI | CHARLIE125 | investorshub | 08/20/2019 1:41:49 PM |
PUMA is looking good and I see more | Brian903 | investorshub | 08/19/2019 8:48:14 PM |
PBYI next aproval next week solid tumors phase | CHARLIE125 | investorshub | 08/15/2019 1:58:03 PM |
JP MORGAN Is in contact with FDA and | CHARLIE125 | investorshub | 08/15/2019 1:55:37 PM |
22th july i said this.You can see it | CHARLIE125 | investorshub | 08/15/2019 1:54:23 PM |
* * $PBYI Video Chart 08-09-2019 * * | ClayTrader | investorshub | 08/09/2019 8:15:27 PM |
Everything You Need For Your Premarket Including PumaBiotechnology | behindthebid | investorshub | 08/09/2019 1:11:37 PM |
$PBYI 3 Months Chart http://www.stockscores.c | $Pistol Pete$ | investorshub | 07/23/2019 3:05:11 PM |
$PBYI current report impresive 7th august | CHARLIE125 | investorshub | 07/22/2019 6:39:33 PM |
Oops! Now what Charlie?? | girlfriend | investorshub | 07/08/2019 3:30:39 PM |
Puma | CHARLIE125 | investorshub | 06/18/2019 6:43:45 AM |
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000 ® Index at the conclusion of Russell Investments’ annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S....